NeuroPace CMO Buys 5,460 Shares & 14,550 Options—Insider Confidence Signals Upward

Insider Activity Spotlight: NeuroPace’s Medical Chief Buys Shares

On 15 May 2026, NeuroPace, Inc. (NASDAQ: NCPA) announced that Chief Medical Officer (CMO) Morrell Martha executed a purchase of 5,460 shares of the company’s common stock at no cash consideration. The transaction constitutes a Restricted Stock Unit (RSU) grant, with 25 % of the shares vesting on 15 May 2027 and the remaining balance vesting in twelve equal quarterly installments. On the same day, CMO Martha also secured 14,550 stock‑option rights at zero cost, granting her the right to purchase shares at a future exercise price.

Market Significance of the RSU Grant

An RSU grant of this magnitude reflects board confidence in NeuroPace’s long‑term prospects and aligns CMO Martha’s interests with those of shareholders. The vesting schedule is designed to encourage retention and long‑term performance. By acquiring 52,743 shares in total, the CMO has demonstrated a willingness to commit substantial equity to the company, signaling optimism about future share‑price appreciation.

Implications of the Stock‑Option Purchase

The acquisition of 14,550 option rights—though dilutive if exercised—indicates a bullish outlook from senior leadership. While the option exercise price and future value remain contingent on the company’s performance, the decision to obtain these rights at zero cost underscores confidence in the company’s trajectory. In a market where NeuroPace’s current trading price of $15.99 sits near a recent 52‑week low of $7.56, the option purchase may be viewed by investors as an endorsement of the company’s potential to recover and grow.

Broader Insider Activity Patterns

Recent company‑wide insider transactions illustrate a mix of buying and selling. CEO Joel Becker purchased 45,880 shares and 122,190 option shares on 15 May 2026. In contrast, CMO Martha has engaged in frequent sales—1,341 shares on 24 March and 1,337 shares on 3 September—often in the 1,300–3,400 share range. These sales, executed at prices between $8.66 and $17.99, appear to be routine market‑making activity rather than panic selling, as they remain above the 52‑week low and below the 52‑week high.

The juxtaposition of Martha’s recent RSU grant and option purchase against her prior sale activity suggests a strategic shift. While continuing to manage personal liquidity through sales, she is simultaneously investing in the company’s future, a strategy common among senior executives who balance personal wealth diversification with shareholder alignment.

Potential Impact on NeuroPace’s Share Price and Dilution

If CMO Martha’s RSUs vest and her options are exercised, NeuroPace could experience modest dilution. However, the net effect is likely to be a positive signal to the market, reinforcing executive confidence in the company’s technology pipeline and market expansion plans. The company’s current valuation, characterized by a negative price‑earnings ratio of –23.3 and a recent quarterly decline of –4.11 %, indicates that share prices are presently undervalued relative to fundamentals, potentially creating upside for long‑term investors.

Investor Takeaway

For investors, the combined insider buying and option purchases by both the CMO and CEO suggest a consensus within executive leadership that NeuroPace’s medical technology and strategic initiatives will drive future share‑price appreciation. This insider activity, coupled with the company’s undervaluation relative to earnings, presents an attractive entry point for patient‑capital investors seeking exposure to a neuro‑stimulation platform with strong growth prospects.